Skip to search formSkip to main contentSkip to account menu

CI 1040

Known as: CI-1040, CI1040 
National Institutes of Health

Related topics

Related topics

1 relation
PD 184352

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Mechanisms of Acquired Resistance to Venetoclax in Preclinical AML Models
BH3-mimetic ABT-199 (venetoclax, VEN) is a selective small-molecule antagonist of the anti-apoptotic BCL-2 protein. It binds to… 
2013
2013
Combination of Rapamycin, CI-1040, and 17-AAG Inhibits Metastatic Capacity of Prostate Cancer via Slug Inhibition
Though prostate cancer (PCa) has slow progression, the hormone refractory (HRCP) and metastatic entities are substantially lethal… 
2012
2012
Killing of Kras-Mutant Colon Cancer Cells via Rac-Independent Actin Remodeling by the βGBP Cytokine, a Physiological PI3K Inhibitor Therapeutically Effective In Vivo
Activating mutations in Kras are the most frequent mutations in human cancer. They define a subset of patients who do not respond… 
2009
2009
Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition.
BACKGROUND The mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway plays an important… 
Highly Cited
2008
Highly Cited
2008
Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways.
BACKGROUND We recently demonstrated inhibition of thyroid cancer cells by the MEK inhibitor CI-1040. The objective of this study… 
2008
2008
Reduction of chronic allograft nephropathy by inhibition of extracellular signal-regulated kinase 1 and 2 signaling.
Chronic allograft nephropathy (CAN), the most common cause of late kidney allograft failure, is not effectively prevented by… 
2008
2008
Pros and cons of cellular studies in developing new drugs for thyroid cancers.
2006
2006
Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration
One specific limitation to the clinical development of targeted cancer therapeutics is the lack of well-validated pharmacodynamic… 
2005
2005
Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cells.
Conditionally active forms of the Raf proteins (Raf-1, B-Raf, and A-Raf) were created by ligating NH2-terminal truncated… 
2003
2003
Effects of the MEK inhibitor CI-1040 (PD 184352) on progenitor growth from normal and myelodysplastic marrow.
1. Peddie CM, Wolf CR, Mclellan LI, Collins AR, Bowen DT. Oxidative DNA damage in CD34+ myelodysplastic cells is associated with… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)